Photo from wikipedia
To evaluate the efficacy and safety of fasiglifam, an orally active G‐protein‐coupled receptor 40 agonist, in combination with the dipeptidyl peptidase‐4 inhibitor sitagliptin, in patients with type 2 diabetes inadequately… Click to show full abstract
To evaluate the efficacy and safety of fasiglifam, an orally active G‐protein‐coupled receptor 40 agonist, in combination with the dipeptidyl peptidase‐4 inhibitor sitagliptin, in patients with type 2 diabetes inadequately controlled with diet/exercise (± metformin).
Keywords:
patients type;
receptor agonist;
fasiglifam;
protein coupled;
coupled receptor;
type diabetes
Journal Title: Diabetes
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!